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Resistance to BRAFV600E inhibitors is associated with reactivation of mitogen-acti-
vated protein kinase (MAPK) signaling at different levels in melanoma. To identify 
downstream effectors of MAPK signaling that could be used as potential additional 
therapeutic targets for BRAFV600E inhibitors, we used hTERT/CDK4R24C/p53DD-
immortalized primary human melanocytes genetically modified to ectopically express 
BRAFV600E or NRASG12D and observed induction of the AP-1 transcription factor 
family member c-Jun. Using a dominant negative approach, in vitro cell proliferation 
assays, western blots, and flow cytometry showed that MAPK signaling via BRAFV600E 
promotes melanoma cell proliferation at G1 through AP-1-mediated negative regula-
tion of the INK4 family member, cyclin-dependent kinase inhibitor 2C (CDKN2C), and 
the CIP/KIP family member, cyclin-dependent kinase inhibitor 1A (CDKN1A). These 
effects were antagonized by pharmacological inhibition of CDKN2C and CDKN1A tar-
gets CDK2 and CDK4 in vitro. In contrast to BRAFV600E or NRASG12D-expressing 
melanocytes, melanoma cells have an inherent resistance to suppression of AP-1 
activity by BRAFV600E- or MEK-inhibitors. Here, CDK2/4 inhibition statistically sig-
nificantly augmented the effects of BRAFV600E- or MEK-inhibitors on melanoma cell 
viability in vitro and growth in athymic nude Foxn1nu mice (P = .03 when mean tumor 
volume at day 13 was compared for BRAFV600E inhibitor vs BRAFV600E inhibitor plus 
CDK2/4 inhibition; P = .02 when mean tumor volume was compared for MEK inhibi-
tor vs MEK inhibitor plus CDK2/4 inhibition; P values were calculated by a two-sided 
Welch t test; n = 4–8 mice per group).
J Natl Cancer Inst 2012;104:1673–1679
Melanoma responses to BRAFV600E inhi-
bition (1,2) are often followed by disease 
recurrence through reactivation of the 
mitogen-activated protein kinase (MAPK) 
pathway (3), a nonlinear dynamic regulatory 
network of protein kinases (4). Resistance 
to BRAFV600E inhibition occurs at different 
levels of this network, eg, through acquisi-
tion of new activating mechanisms such as 
mutations in NRAS or MEK (5,6), MEK 
kinase activation and CRAF overexpres-
sion (7), activation of alternative wild-type 
RAF heterodimers (8), or activation of 
platelet-derived growth factor receptor β 
(5) and insulin-like growth factor 1 recep-
tor via functional cross-talk (8). Thus, we 
hypothesized that inhibition of down-
stream effectors of MAPK signaling could 
be a potential therapeutic strategy for 
BRAFV600E inhibitor-resistant melanomas. 
To our knowledge, this therapeutic strategy 
has not been explored for melanoma.
To identify downstream effectors of 
MAPK signaling that could be used as poten-
tial therapeutic targets, we used hTERT/ 
CDK4R24C/p53DD-immortalized primary 
human melanocytes genetically modified to 
ectopically express BRAFV600E or NRASG12D 
(9). Protein lysates were subjected to west-
ern blot for activated and total c-Jun, an 
oncogenic subunit of the AP-1 transcrip-
tion factor (Supplementary Methods, avail-
able online). AP-1 is a homo/heterodimeric 
transcription factor composed of c-Jun and 
JunD homo- or hetero  dimers, or hetero-
dimers with other basic leucine-zipper 
family members (10), and is a major trans-
ducer of cellular proproliferative signals 
(10,11). We found that ectopic expression 
of BRAFV600E or NRASG12D increased activa-
tion of c-Jun relative to parental hTERT/
CDK4R24C/p53DD cells (Figure  1,  A). 
Furthermore, when the cells were treated 
with the MEK1/2 inhibitor PD98059 (12) 
(Selleck Chemicals, Houston, TX), AP-1 
activity was markedly decreased compared 
with untreated and solvent (control)-
treated cells as detected by an AP-1-
secreted alkaline phosphatase reporter 
gene assay (Supplementary Methods, avail-
able online).
To determine the effect of c-Jun knock-
down on MAPK signaling in human 
melanoma cells, LOXIMVI cells were tran-
siently transfected with three different small 
interfering RNAs (siRNAs) targeting c-Jun 
(Supplementary Methods, available online). 
After 48 hours, c-Jun knockdown was con-
firmed by western blot, and siRNA #145018 
was used for all subsequent experiments (data 
not shown). siRNA transfected-LOXIMVI 
cells had decreased AP-1 activity relative 
to cells transfected with a nontarget con-
trol siRNA (mean AP-1 activity = 65.2%, 
SD = 18.4% vs 100%, SD = 7.0%, two-sided 
P = .07) (Supplementary Figure 1, A, availa-
ble online). c-Jun knockdown also increased 
the percentage of cells in G1 compared with 
the nontarget control siRNA (21.5% vs 
12.1%, data from one representative experi-
ment), whereas the percentage of cells in S 
and G2M remained similar (Supplementary 
Methods, available online). Cell prolifera-
tion of c-Jun siRNA transfected cells was 
also decreased compared with nontarget 
siRNA transfected cells (mean cell num-
ber on day 4 = 8.6 x 103, SD = 0.2 x 103 vs 
24.9 x 103, SD = 2.9 x 103, respectively, two-
sided  P  =  .01) (Supplementary Methods 
and Supplementary Figure  1, B, available 
online).
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Figure 1.  Mitogen-activated protein kinase, AP-1 activity, and proliferation 
of human melanocytic cells. A) Results of western blots for c-Jun and phos-
phorylated c-Jun (p-cJun) protein expression levels in primary immortal-
ized human melanocytes (hTERT/C4(R24C)/p53DD) with or without ectopic 
expression of a BRAFV600E or NRASG12D are shown (left panel). AP-1 activ-
ity in these cells was measured by AP-1-secreted alkaline phosphatase 
reporter gene assay after treatment with the MEK inhibitor PD098059 
(50  µM) or dimethyl sulfoxide (right panel). Untreated cells served as 
an additional control. Results are representative of two independent 
experiments performed in triplicate. B) AP-1 activity was also measured in 
the NCI-60 BRAFV600E human melanoma LOXIMVI cell line, stably express-
ing dominant negative AP-1 and a puromycin resistance gene (-dnAP-1) 
or the resistance gene alone (-empty vector) with (0.75 µg/mL puromy-
cin) and without induction (0.25 µg/mL puromycin) of the transgene for 48 
hours. Whisker bars indicate the SD. Results are representative of three 
independent experiments performed in triplicate. C) Cell proliferation of 
LOXIMVI-dnAP-1 cells upon induction of dnAP-1 as determined by cell 
numbers over time. The means and corresponding SD (whisker bars) of JNCI | Brief  Communication 1675 jnci.oxfordjournals.org
Transfection of the LOXIMVI mela-
noma cell line with a dominant negative 
c-Jun mutant (dnAP-1), which leads to a 
broader inhibition of AP-1 activity by bind-
ing additional AP-1 members compared 
with c-Jun siRNA (13), was done with the 
bicistronic pIRESpuro3 vector (Clontech 
Laboratories, Mountain View, CA) to sta-
bly express a puromycin resistance gene 
with or without a FLAG-tagged dnAP-1 
(14) (referred to hereafter as -dnAP-1 and 
-empty vector cells, respectively). When 
cultured in a low concentration of puromy-
cin (0.25 µg/mL), LOXIMVI-dnAP-1 cells 
expressed low levels of the resistance gene 
and dnAP-1 without an impact on AP-1 
activity (Figure  1,  B), cell proliferation, 
or cell cycle distribution (data not shown) 
compared with LOXIMVI-empty-vector 
cells. When cultured at a high concentra-
tion of puromycin (0.75  µg/mL), LOX-
IMVI-dnAP-1 cells expressed high levels of 
dnAP-1 in the cytoplasm and the nucleus 
(Supplementary Figure 1, C and D, avail-
able online) and showed decreased AP-1 
activity (mean AP-1 activity  =  26.5%, 
SD = 16.5% vs 75.3%, SD = 8.3%, respec-
tively, two-sided P  =  .02) (Figure  1,  B), 
decreased cell proliferation (mean cell 
number at day 5 = 4.1 x 104, SD = 0.2 x 104 
vs 37.9 x 104, SD = 0.6 x 104, respectively, 
two-sided  P < .001) (Figure  1,  C), accu-
mulation of cells in G1 (Figure 1, D), and 
decreased [3H]thymidine uptake (data not 
shown) compared with culturing at a low 
concentration of puromycin.
To investigate the effect of AP-1 inhi-
bition in melanoma cells in vivo, 1 x 106 
LOXIMVI-dnAP-1 cells were injected 
subcutaneously into female, 6–8-week-old, 
athymic nude Foxn1nu mice (Supplementary 
Methods, available online). Animal care 
procedures followed the guidelines of 
the Animal Research Committee of the 
Medical University of Vienna. Injection 
of LOXIMVI-dnAP-1 xenografts with 
0.75  µg/mL puromycin every other day 
inhibited tumor growth compared with 
xenografts injected with 0.25 µg/mL puro-
mycin (Figure 1, E), indicating that AP-1 
activity is required for in vivo growth of 
human melanoma cells.
Because the effects of induced expres-
sion of dnAP-1 on cell proliferation (by 
counting cell numbers over time, Figure 1, 
C and Supplementary Figure 1, E, avail-
able online) and cell cycle distribution (not 
shown) were similar in human UACC257 
melanoma cells and LOXIMVI cells that 
are cyclin-dependent kinase inhibitor 
CDKN2A–deficient, we investigated the 
effect of dnAP-1 on the expression of other 
cell cycle regulators at G1 by western blot. 
We found that CDKN2C and CDKN1A 
protein levels in LOXIMVI-dnAP-1 cells 
were increased relative to LOXIMVI 
empty vector cells within 2 hours of induc-
tion of dnAP-1 with puromycin (Figure 1, 
F). CDKN2D, CCND1, and CDK6 pro-
tein levels increased later at 12 and 16 hours 
after dnAP-1 induction in both LOX-
IMVI-dnAP-1 and LOXIMVI-empty 
vector cells. CDK2 and CDK4 protein 
levels remained almost unchanged within 
24 hours (Figure 1, F and Supplementary 
Figure 1, F, available online). In addition, 
we observed nuclear and cytoplasmic 
accumulation of CDKN2C and nuclear 
accumulation of CDKN1A by immuno-
fluorescence in LOXIMVI-dnAP-1 cells 
48 hours after induction of dnAP-1 using 
puromycin (Supplementary Figure  1, G 
and H, available online).
Consistent with these findings, trans-
fection of LOXIMVI cells with siRNA 
targeting CDKN2C or CDKN1A in vitro 
partially rescued dn-AP1-induced sup-
pression of cell proliferation, and when 
both CDKN2C and CDKN1A siRNAs 
were cotransfected into LOXIMVI cells, 
cell proliferation (as measured by count-
ing cell numbers over time, which is shown 
in Figure 1, G, and [3H]thymidine uptake 
[data not shown]) was similar to that of 
LOXIMVI-empty vector control cells. 
Similar effects were not seen when siRNA 
targeting other cell cycle regulators (TP53, 
CDKN1B, CDKN1C alone or in combi-
nation with CDKN2C) was used (data not 
shown). These results indicate that the full 
proproliferative effect of AP-1 on melanoma 
cells requires suppression of both the INK4 
family member CDKN2C and the CIP/
KIP family member CDKN1A. This find-
ing supports a previous report in which the 
ability of CDK4R24C (an INK4-insensitive 
CDK4 mutant) to rescue Cdkn1a−/− but 
not Cdkn1awt cells from growth arrest (15), 
an important prerequisite for cell trans-
formation, was described. Furthermore, 
mutations in CDK4 have been described in 
melanoma-prone families and patients with 
multiple primary melanomas (16),  CDK4 
amplification has been previously reported 
in subtypes of sporadic melanoma (17), and 
reduced CDKN1A expression has been 
implicated in melanoma metastasis (18).
As AP-1 is a transcription factor, 
we performed cotransfection assays 
with wild-type CDKN2C and CDKN1A 
promoter-luciferase reporter plasmids 
(19,20) in LOXIMVI-dnAP-1 and LOX-
IMVI-empty vector cells. When cultured 
at a high concentration of puromycin 
(0.75  µg/mL) for 4 hours, LOXIMVI-
dnAP-1 cells showed activated expression 
from both promoter reporter plasmids 
compared with LOXIMVI-empty vec-
tor cells (mean fold CDKN2C promoter 
a representative experiment performed in triplicate are shown. Four inde-
pendent experiments were performed with similar results. D) Cell cycle 
analysis was performed by flow cytometry of propidium iodide–stained 
LOXIMVI-dnAP-1 cells 48 hours after induction of dnAP-1 with a high con-
centration (0.75 µg/mL) of puromycin and compared with LOXIMVI-dnAP-1 
cells exposed to a low concentration (0.25 µg/mL) of puromycin. The per-
centages of cells in G1, S, and G2 phases of the cell cycle are shown. E) 
In vivo growth of LOXIMVI-dnAP-1 cells was measured in athymic nude 
Foxn1nu mice (n = 6 mice per group) with or without induction of dnAP-1 by 
injection of 50 µL of low (0.25 µg/mL) or high (0.75 µg/mL) concentrations 
of puromycin in phosphate buffered saline every other day. Whisker bars 
indicate the upper SD. F) Western blot of cell lysates with anti-CDKN2C, 
dnAP-1/c-Jun, CDKN2D, CDKN1A, α-tubulin antibodies of LOXIMVI-dnAP-1 
and -empty vector cells was done at 0, 2, 12, and 16 hours after induction 
of dnAP-1. This experiment was performed three times with similar results. 
G) Cell proliferation was determined by counting LOXIMVI-dnAP-1 cell 
numbers after induction of dnAP-1 and transfection with small interfering 
RNAs (siRNAs) targeting CDKN2C, CDKN1A, or CDKN1A and CDKN2C. 
As a reference, LOXIMVI-empty vector cells were treated with nontarget 
small interfering RNA (nt siRNA). siRNA transfection was confirmed by 
western blot (inset). The means with SD (whisker bars) are given. Results 
are representative of three independent experiments performed in tripli-
cate. H) Chromatin immunoprecipitation assay of LOXIMVI cells was done 
with anti-c-Jun antibody and polymerase chain reaction primer sets for 
the β-ACTIN and CDKN2C promoters (Prom#1, #2, and #3) and enhancer 
(EnhU and EnhD) regions (left panel). Quantitative polymerase chain reac-
tion signals for Prom#1, EnhU, and EnhD regions were normalized to the 
input and expressed as the mean with SD (whisker bars). As a control, the 
anti-c-Jun antibody was substituted with IgG (right panel). The results are 
representative of two independent experiments.
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Figure  2.  Melanoma cell viability and in vivo growth by cyclin-
dependent kinase 2/4 inhibition. A) Cell viability was assessed by 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium-bromide assay 
of human melanoma cell lines (white, gray, and black bars indicate 
BRAFwt/NRASwt,  NRASQ61R, and BRAFV600E cell lines, respectively) 
treated with a CDK2/4 inhibitor combination (2  µM CVT313 plus 
0.25  µM indolocarbazole CDK4-I) for 48 hours. The values are pre-
sented as the percentage of treatment with dimethyl sulfoxide (DMSO, 
solvent). Whisker bars indicate the SD (left panel). On-target effects 
of CDK2/4 inhibitors in LOXIMVI cells are shown in the right panel: 
cell cycle analysis by flow cytometry was done after treatment with 
DMSO (solvent) control or the CVT313/indolocarbazole CDK4-I com-
bination for 12 hours; western blot analysis was also done to detect 
phosphorylated retinoblastoma (p-RB) (Thr826) levels after treatment 
with DMSO (solvent) control, 2 µM CVT313, or 0.25 µM indolocarba-
zole CDK4-I for 48 hours. These experiments were performed three JNCI | Brief  Communication 1677 jnci.oxfordjournals.org
induction for LOXIMVI-dnAP-1 cells 
vs LOXIMVI-empty vector cells  =  3.1, 
SD  =  0.2 vs 1.0, SD  =  0.02, two-sided 
P = .002; mean fold CDKN1A promoter 
induction for LOXIMVI-dnAP-1 cells 
vs LOXIMVI-empty vector cells  =  1.7, 
SD  =  0.1 vs 1, SD  =  0.1, two-sided P 
< .001) (Supplementary Methods and 
Supplementary Figure 2, A, available 
online), further supporting the link between 
AP-1 activity and CDKN2C and CDKN1A 
expression. As dn-AP-1 induced CDKN2C 
mRNA in LOXIMVI-dnAP-1 cells (by 
quantitative reverse transcription-real time 
PCR, data not shown) independent of pro-
tein synthesis (by cycloheximide, data not 
shown), we performed chromatin immuno-
precipitation from LOXIMVI cells with an 
anti-c-Jun antibody followed by polymerase 
chain reaction using primer sets spanning 
putative AP-1-binding sites at the CDKN2C 
gene (21) (Supplementary Methods, avail-
able online). We observed binding of AP-1 
at two promoter-distant regions upstream 
and downstream of CDKN2C, each har-
boring a 12-O-tetradecanoate-13-acetate 
response element-binding motif, and one 
region within the promoter (Figure 1, H). 
These results indicate that CDKN2C is a 
direct target of AP-1.
In addition, we assessed the relation-
ship between c-Jun expression and that of 
CDKN2C and CDKN1A using RNA and 
tissues obtained from 30 melanoma patients. 
The primary human melanomas were 
assigned to two groups (low and high) based 
on low vs high expression of CDKN2C 
and CDKN1A (mean relative CDKN2C 
mRNA expression = 0.5, SD = 0.3 vs 2.5, 
SD = 1.8, respectively, two-sided P = .007; 
mean relative CDKN1A mRNA expres-
sion  =  0.9, SD  =  0.4 vs 3.0, SD  =  1.2, 
respectively, two-sided P < .001; n = 8 and 
11, respectively) as determined by quan-
titative real-time PCR of available RNA 
(Supplementary Methods, available online). 
Nuclear phospho-c-Jun expression in the 
corresponding tissues was then analyzed 
by immunohistochemistry (Supplementary 
Methods, available online), and the per-
centage of cells with 0–1+, 2+, and 3+ stain-
ing was determined. A table summarizing 
the data and representative stained tissues 
are depicted in Supplementary Figure 2, B 
(available online). High levels of CDKN2C 
and CDKN1A mRNA were associated with 
low phospho-c-Jun staining (0–1+), whereas 
low levels of CDKN2C and CDKN1A 
mRNA were associated with high phospho-
c-Jun staining (2+ and 3+). These results 
further substantiate the role of AP-1 in 
the negative regulation of CDKN2C and 
CDKN1A transcription. In accordance 
with these results, previous studies in ani-
mal models have shown that CDK4R24C and 
a CDKN2C deficiency increase melanoma 
susceptibility, but additional MAPK signal-
ing is required for melanomas to develop 
(22,23).
Because the expression of CDKN2C 
and CDKN1A targets, ie, CDK2 and 
CDK4/6, was unaffected by dnAP-1 
(Supplementary Figure  1, F, available 
online) and is rarely lost in human mela-
noma (24), our results provide rationale 
for the development of novel combina-
tion therapeutic strategies for melanoma. 
In contrast to single agent-treatment with 
inhibitors at doses selective to CDK2 or 
CDK4 inhibition [NU6140 (25), CVT-313 
(26), NSC625987 (27), indolocarbazole 
CDK4-I (28)] (Supplementary Methods 
and Supplementary Figure  2, C, avail-
able online), the combination of CDK2/4 
inhibitors reduced viability in a panel of 
melanoma cell lines (by 3-[4,5-dimeth-
ylthiazol-2-yl]-2,5-diphenyltetrazolium- 
bromide assay) (Figure 2, A) and statistically 
significantly the growth of LOXIMVI xen-
ografts in vivo (mean tumor volume at day 
13: vehicle only = 1.5 x 103 mm3, SD = 0.5 
x 103 mm3; 0.75/0.1 mg/kg dose level = 0.9 
x 103 mm3, SD = 0.2 x 103 mm3; 1.5/0.2 mg/
kg dose level = 0.6 x 103 mm3, SD = 0.3 x 
103 mm3; vehicle vs 0.75/0.1  mg/kg dose, 
two-sided  P  =  .05; vehicle vs 1.5/0.2  mg/
kg dose, two-sided P = .01; n = 6–8 mice 
per group) (Figure  2,  B). Reduction of 
viability was independent of the presence 
or absence of BRAFV600E/NRASQ61R as were 
nuclear phospho-c-Jun and CDKN2C/
CDKN1A transcript levels in primary mel-
anomas. Furthermore, in BRAFV600E mela-
noma cells, the highly selective BRAFV600E 
inhibitor GDC-0879 (29) and three selec-
tive MEK inhibitors [PD184352/CI-1040 
(30), U0126 (31), PD98059 (12)] did 
not suppress c-Jun levels, although they 
effectively reduced phospho-ERK levels 
(Figure  2,  C). Together these data sug-
gest that in melanoma cells, in contrast 
to melanocytes, pathways that bypass the 
BRAF-MEK-ERK axis to induce AP-1 are 
operative. Consistent with this hypothesis, 
AP-1 and CDK2/4 inhibition increased the 
magnitude of the reduction of melanoma 
cell viability/proliferation by BRAFV600E 
inhibitor GDC-0879 and MEK inhibitor 
PD184352/CI1040 in vitro (Figure  2,  D 
and Supplementary Figure 2, D, available 
times with similar results. B) In vivo growth of LOXIMVI xenograft 
tumors in athymic nude Foxn1nu mice systemically treated with the 
CDK2/4 inhibitor combination (CVT-313 plus indolocarbazole CDK4-I) 
is shown. Growth reduction was observed by comparison of vehicle 
only vs 0.75/0.1 mg/kg (P = .05) and 1.5/0.2 mg/kg (P = .01) dose levels 
(n = 6–8 mice per group, two-sided Welch’s t test was used to calcu-
late P). Whisker bars indicate the upper or lower SD. C) Western blot 
analysis for c-Jun, phosphorylated-ERK1/2 (Thr202/Tyr204) (p-ERK1/2), 
and total ERK1/2 protein levels was done for human melanoma cell 
lines treated with the BRAFV600E inhibitor GDC-0879 (1 µM), or MEK 
inhibitors CI-1040 (1 µM), U0126 (1 µM), and PD98059 (10 µM) for 18 
hours. Glyceraldehyde 3-phosphatase dehydrogenase (GAPDH) was 
used as the loading control. This experiment was performed three 
times with similar results. D) Cell viability of HT144, LOXIMVI, and 
WM115 human melanoma cell lines after exposure to different com-
binations of CDK2/4 with MEK- and BRAFV600E-inhibitors was assessed 
by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium-bromide assay 
after 72 hours. Simultaneous treatment with the indicated CDK2/4 
inhibitor combinations [NU6140 (2 µM) plus NSC625987 (20 µM) or 
CVT-313 (2 µM) plus indolocarbazole CDK4-I (0.25 µM)] decreased the 
dose of MEK- and BRAFV600E-inhibitors required to reduce melanoma 
cell viability by 75% (viability25). Whisker bars indicate the SD. Results 
are representative of four independent experiments performed in 
triplicates. E and F) In vivo growth of LOXIMVI xenografts in athymic 
nude Foxn1nu mice is shown. Tumors were allowed to grow to a maxi-
mum volume of 250  mm3, and the mice were subsequently treated 
daily at the indicated dose levels with CDK2/4 inhibitors by intraperi-
toneal injection in combination with a BRAFV600E- or MEK-inhibitor. E) 
CDK2/4 inhibitor (CVT-313/indolocarbazole CDK4-I) treatment sensi-
tizes tumors to systemic treatment with BRAFV600E inhibitor GDC-0879 
(GDC-0879 vs GDC-0879 plus CVT-313/indolocarbazole CDK4-I: P = .03, 
n = 5–8 per group, two-sided Welch’s t test). F) CDK2/4 inhibitor (CVT-
313/indolocarbazole CDK4-I) treatment sensitized tumors to systemic 
treatment with MEK-inhibitor CI1040 (CI1040 vs CI1040 plus CVT-313/
indolocarbazole CDK4-I; P = .02, n = 4–8 per group, two-sided Welch’s t 
test). Whisker bars indicate the upper SD.
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online), and CDK2/4 inhibition augmented 
statistically significant growth reduction of 
melanoma xenografts in vivo by the BRAF 
and MEK inhibitors (P = .03 when mean 
tumor volume at day 13 was compared for 
GDC-0879 vs GDC-0879 plus CDK2/4 
inhibition; P = .02 when mean tumor vol-
ume was compared for PD184352/CI1040 
vs PD184352/CI1040 plus CDK2/4 inhibi-
tion; n = 4–8 mice per group) (mean tumor 
volume at day 13: GDC-0879 = 0.7 x 103 
mm3, SD  =  0.2 x 103 mm3; GDC-0879 
plus CDK2/4 inhibition = 0.3 x 103 mm3, 
SD = 0.2 x 103 mm3; GDC-0879 vs GDC-
0879 plus CDK2/4 inhibition, two-sided 
P = .03; PD184352/CI1040 = 0.4 x 103 mm3, 
SD  =  0.2 x 103 mm3; PD184352/CI1040 
plus CDK2/4 inhibition = 0.2 x 103 mm3, 
SD = 0.1 x 103 mm3; PD184352/CI1040 vs 
PD184352/CI1040 plus CDK2/4 inhibi-
tion, two sided P = .02; n = 4–8 mice per 
group) (Figure 2, E and F).
Our study was not without limitations. 
The restricted ability of cell-based studies 
to predict clinical behavior is an inherent 
restraint. Also, the varied response to cyc-
lin-dependent kinase inhibitors between 
different melanoma cell lines is unexplained 
at this time. The small number of available 
human tissue samples used in our study also 
limits the interpretation of our results.
Nevertheless, our data show a sta-
tistically significant augmentation of 
BRAFV600E- and MEK-inhibitors by 
CDK2/4 inhibition in vivo. Our findings 
provide rationale and support for further 
clinical exploration of this novel combina-
tion therapeutic strategy for melanoma.
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